DE3147727A1 - Wound-healing composition containing collagen from basement membranes - Google Patents
Wound-healing composition containing collagen from basement membranesInfo
- Publication number
- DE3147727A1 DE3147727A1 DE19813147727 DE3147727A DE3147727A1 DE 3147727 A1 DE3147727 A1 DE 3147727A1 DE 19813147727 DE19813147727 DE 19813147727 DE 3147727 A DE3147727 A DE 3147727A DE 3147727 A1 DE3147727 A1 DE 3147727A1
- Authority
- DE
- Germany
- Prior art keywords
- collagen
- basement membrane
- wound
- wound healing
- membrane collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 45
- 108010035532 Collagen Proteins 0.000 title claims abstract description 45
- 229920001436 collagen Polymers 0.000 title claims abstract description 45
- 210000002469 basement membrane Anatomy 0.000 title claims abstract description 36
- 230000029663 wound healing Effects 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 title abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 8
- 239000003357 wound healing promoting agent Substances 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 230000000855 fungicidal effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 abstract description 4
- 238000011069 regeneration method Methods 0.000 abstract description 4
- 239000000654 additive Substances 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000057297 Pepsin A Human genes 0.000 description 6
- 108090000284 Pepsin A Proteins 0.000 description 6
- 229940111202 pepsin Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000035874 Excoriation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 231100000075 skin burn Toxicity 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229960002796 polystyrene sulfonate Drugs 0.000 description 1
- 239000011970 polystyrene sulfonate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/408—Virucides, spermicides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Description
Wundheilmittel enthaltend Kollagen aus BasalmembranenWound healing agents containing collagen from basement membranes
Die vorliegende Erfindung betrifft ein Wundheilmittel welches Basalmembrankollagen und gegebenenfalls übliche Träger- und Hilfsstoffe enthält.The present invention relates to a wound healing agent which contains basement membrane collagen and optionally contains customary carriers and auxiliaries.
Bisher hat man zur Förderung der Wundheilung z.B. Prostaglandine enthaltende Mittel vorgeschlagen (vgl. US-A-4061670). In der GB-A-1565340 wurden enzymatisch abgebaute menschliche und tierische Gewebe für die Wundheilung beschrieben. Interstitielle Kollagene sollen gemäß DE-OS 2462222 zur Heilung von Bindegewebserkrankungen- eingesetzt werden.So far, one has, for example, containing prostaglandins to promote wound healing Means proposed (see US-A-4061670). In GB-A-1565340 were enzymatic degraded human and animal tissues for wound healing are described. Interstitial According to DE-OS 2462222, collagens are used to heal connective tissue diseases will.
Es wurde nun gefunden, daß Basalmembrankollagen zu einer besonders schnellen Wundheilung führt, wobei die Narben besonders schön verheilen.It has now been found that basement membrane collagen becomes a particular leads to rapid wound healing, with the scars healing particularly nicely.
Durch die vorliegende Erfindung wird ein hochwirksames neues Mittel zur Heilung von Wunden verschiedenster Art bereitgestellt.The present invention provides a highly effective new agent provided for the healing of wounds of various types.
Das Mittel ist auch besonders geeignet zur Heilung von Verbrennungswunden und von Sonnenbrand.The agent is also particularly suitable for healing burn wounds and from sunburn.
Es wurde überraschend gefunden, daß es neben interstitiellen Kollagenen im Bindegewebe noch eine kollagene Variante in Basalmembranen gibt. Die Basalmembranen haben im Vergleich zum Bindegewebe völlig andere Funktionen und auch die Struktur ist verschieden. Die Basalmelnbranen liegen zwischen parenchymalen Zellen und dem Bindegewebe bzw. Stützgewebe.It was surprisingly found that there were interstitial collagens there is still a collagen variant in the basement membrane in the connective tissue. The basement membranes have completely different functions and structure compared to connective tissue is different. The basement membranes lie between the parenchymal cells and the Connective tissue or supporting tissue.
Parechymale Zellen sind die epithelialen Zellen der Epidermis und epidermalen eiLen des Harn-, Genital-, Respirations-und Ga6trointestihaltraktes sowie alle exokrinen Düsen, endothelialen Zellen des cardiovaskuldren Systems, die mesothelialen Zellen von Körperhohlräumen und Zellen des zentrales und periphären Nervensystems, endokrinen Zellen, Muskelfasern und Fettzellen. Die Basalmembranen stellen somit den Abschluf? des endothelialen bzw. epithelialen Gewebes gegenüber Bindegewebe dar und vermitteln gleichzeitig eine enge Verbind dung der verschiedenen Gewebe. Sie kommen stets nur in geringen Ilengen jedoch praktisch über den ganzen Körper verteilt vor. Die wichtigste Aufgabe der Basalmembran ist ihre Filtrationsfunktion; so kommt die Membran dort in größerer Menge vor, wo spezifische Filtrationsaufgaben zu lösen sind.Parechymal cells are the epithelial cells of the epidermis and epidermal parts of the urinary, genital, respiratory and gastrointestinal tracts as well as all exocrine nozzles, endothelial cells of the cardiovascular system that mesothelial cells of body cavities and cells of the central and peripheral nervous system, endocrine cells, muscle fibers and fat cells. The basement membranes thus represent the conclusion? of the endothelial or epithelial tissue Connective tissue and at the same time provide a close connection between the various Tissue. They always come only in small amounts, but practically over the whole Body distributed in front. The most important task of the basement membrane is its filtration function; so the membrane occurs in larger quantities where specific filtration tasks are concerned are to be solved.
Solche Organe sind z.B. Lunge, Niere, Auge, Plazenta etc.Such organs are e.g. lungs, kidneys, eyes, placenta etc.
Ihr Hauptbestandteil sind kollagene Komponenten und Glykoproteine.Their main components are collagenous components and glycoproteins.
Die Isolierung der Basalmembran bzw. ihrer Komponenten erfordert völlig andere Maßnahmen als sie beim interstitiellen Bindegewebe bzw. interstitiellen Kollagen angewandt werden.The isolation of the basement membrane or its components requires completely measures other than those for interstitial connective tissue or interstitial collagen can be applied.
Die Membran ist nicht nur in geringen Mengen vorhanden, sondern sie ist auch unter physiologischen Bedingungen unlöslich, d.h. durch einfache Neutralsalzextraktion, wie sie bei interstitiellen Kollagenen angewandt wird, nicht zu gewinnen.Not only is the membrane present in small quantities, but it is is also insoluble under physiological conditions, i.e. by simple neutral salt extraction, as it is used with interstitial collagens, not to be gained.
Man geht bei der Isolierung der Basalmembran bzw. ihrer Komponenten so vor, daß durch Verwendung von Detergentien und anderen Hilfstoffen die Membran aus membanreichen Organen extrahiert. In relativ hoher Reinheit werden Bestandteile der Membran erhalten wenn das zëkleinerte Organ mit denaturieren den Agentien, wie z.B. Harnstoff, unter gleichzeitiger Reduktion von Disulfidbrücken, behandelt wird. Noch wirkungsvolier kann die Membran durch proteolytischen Abbau in Lösung gebracht werden. Die sich anschließende Separation des sehr komplexen Gemisches führt dann zur Gewinnung des erfindungsgemäß verwendeten Materials.One goes to isolate the basement membrane or its components so that by using detergents and other auxiliaries, the membrane extracted from membrane-rich organs. Components are of a relatively high purity of the membrane get when the zëkleinerte organ with denature the agents, such as e.g. urea is treated with simultaneous reduction of disulfide bridges. The membrane can still be brought into solution by proteolytic degradation will. The subsequent separation of the very complex mixture then leads for obtaining the material used according to the invention.
Wie sich nun gezeigt hat weisen die Basalmembrankollagene ganz charakteristische Unterschiede gegenüber den interstitiellen Kollagenen auf. Prinzipiell gleich ist der Gehalt an Glycin (7/3) und Prolin und Hydroxyprolin(1/5). Auch der * siehe Fußnote Seite 4 Gehalt an Histidin, Valin,Methionin und Tyrosin ist ähnlich.As has now been shown, the basement membrane collagens have very characteristic properties Differences compared to the interstitial collagens. In principle is the same the content of glycine (7/3) and proline and hydroxyproline (1/5). Also the * see footnote page 4 Histidine, valine, methionine and tyrosine levels are similar.
Charakteristisch für Basalmembrankollagen ist aber der hohe Hydroxylierungsgrad des Prolins und des Lysins. Der Hydroxylysingehalt ist mit 40 -60 Resten pro- 1Ö00 Aminosäuren bedeutend größer als im interstitiellen Kollagen, wo er nur 4 - 24 Reste beträgt. Nahezu alle Hydroxylysinreste sind außerdem mit Mono- oder Disacchariden substituiert. Der Anteil an Aminosäuren mit unpolaren Seitenketten ist bedeutend größer; im Gegensatz zu interstitiellem Kollagen enthält Basalmembrankollagen Cystein, und zwar je nach Ausgangsgewebe in verschiedenen Konzentrationen.However, the high degree of hydroxylation is characteristic of basement membrane collagen of proline and lysine. The hydroxylysine content is 40-60 residues per 1Ö00 Amino acids are significantly larger than in interstitial collagen, where there are only 4 - 24 residues amounts to. Almost all hydroxylysine residues are also mono- or disaccharides substituted. The proportion of amino acids with non-polar side chains is significant greater; unlike interstitial collagen, basement membrane collagen contains cysteine, in different concentrations depending on the starting tissue.
Diese Unterschiede in Struktur und Zusammensetzung bewirken ein unterschiedliches Verhalten bei äußerlicher Anwendung auf menschlicher und tierischer Haut.-Das vorliegend verwendete Kollagen hat- die Fähigkeit der Stimulierung der an die Basålmeml)ran angrenzenden endotlielialen bzw. epithelialen Zellen, was sich dadurch äußert, e daß es zu einer Regenration, beschleunigten Neubildung von liautzellen kommt, sodaß das durch Verletzung oder Verbrennung zerstörte Geweoe i.l kürzester Zeit wieder funktionsfähig ist.These differences in structure and composition have a different effect Behavior when used externally on human and animal skin.-The present The collagen used has the ability to stimulate the Basålmeml) ran adjacent endotlial or epithelial cells, which is expressed by e that it comes to a regeneration, accelerated formation of new cells, so that the tissue tissue destroyed by injury or burns again in a very short time is functional.
Die erfindungsgemäßen Mittel können auch vorteilhaft für die Nachbehandlung von nicht schon vernarbten Wunden oder Operationsnarben eingesetzt werden. Auch bei Hautausschlägen bei denen leicht Male bzw. Hautverfärbungen zurückbleiben, kann durch vermehrte Zellneubildung ein positiver Effekt erzielt werden.The agents according to the invention can also be advantageous for aftertreatment used for wounds that have not already healed or surgical scars. Even for skin rashes that can easily leave marks or discolouration of the skin a positive effect can be achieved through increased cell regeneration.
Basalmembrankollagen zeigt bereits in sehr geringer Konzentration von 0,005% reproduzierbare Beschleunigung der Hautzellenneubildung bzw. Regeneration des zerstörten Gewebes. Verträglichkeitstests haben gezeigt, daß es auch bei Anwendung von großen Konzentrationen, z.B. von 10%igen Lösungen zu keinerlei unerwünschten Nebeneffekten bei externer Anwendung kommt.Basement membrane collagen shows even in very low concentrations 0.005% reproducible acceleration of new skin cell formation or regeneration of the destroyed tissue. Tolerance tests have shown that it is also when used from high concentrations, e.g. from 10% solutions, to no undesirable Side effects comes with external application.
* Biology and Chemistry of Basment Membranes, N. A. Kefalides Academic Press, 43, 1978; A. Rauter, Untersuchung von Basalmembrankollagen aus menschlicher Plazenta, LMU München, 1980.* Biology and Chemistry of Basment Membranes, N.A. Kefalides Academic Press, 43, 1978; A. Rauter, Investigation of basement membrane collagen from human Placenta, LMU Munich, 1980.
Zur Verwendung in Wundheilmittelri kann Basalmembrankollagen mit üblichen Träger und Hilfsstoffen sowie gegebenfalls in Kombination mit Desinfektionsmitteln, bactericiden und oder fungiciden Substanzen, zu Lösungen, Emulsionen, Salben, Pasten, Gelen, Pudern oder Sprays verarbeitet werden. Für flüssige Zubereitungen können als Lösungsmittel Wasser oder übliche organische Lösungsmittel, besonders Alkohol oder DMSO verwendet werden. Man kann auch ansich bekannte Lösungsvermittler einarbeiten. Als Hilfsmittel können unter anderem Emulgiermittel wie äthoxylierte Fettalkohole, Fettsäurealkanolamine, ParaSinöle, Stärke oder Methylcellulose und Konservierungsmittel, aber auch Verdickungsmittel zugefügt werden. Als Trägerstoff können beispielsweise Zellstoff oder hautverträgliche Kunststoffe, wie sie für die Herstellung von Verbandsmaterialien Verwendung finden, genannt werden.For use in wound healing agents, basement membrane collagen can be combined with usual Carriers and auxiliary materials and, if necessary, in combination with disinfectants, bactericidal and / or fungicidal substances, to solutions, emulsions, ointments, pastes, Gels, powders or sprays can be processed. For liquid preparations you can as a solvent, water or customary organic solvents, especially alcohol or DMSO can be used. Solubilizers known per se can also be incorporated. Emulsifiers such as ethoxylated fatty alcohols, Fatty acid alkanolamines, para-sin oils, starch or methyl cellulose and preservatives, but also thickeners can be added. As a carrier, for example Cellulose or skin-friendly plastics, such as those used in the manufacture of dressing materials Can be used.
Erfindungsgemäß kann das Basalmembrankollagen auch in reiner Form ( das heißt in bis zu 100%iger Konzentration) z.B. als faseriges oder pulverisiertes gefriergetrocknetes Material oder gegebenenfalls bedingt durch das Isolierverfahren mit interstitiellen Kollagenen vermischt, angewendet werden.According to the invention, the basement membrane collagen can also be used in pure form (i.e. in up to 100% concentration) e.g. as fibrous or pulverized Freeze-dried material or possibly due to the isolation process mixed with interstitial collagens.
Das erfindungsgemäß verwendbare Kollagen ist zu Beispiel aus humaner Plazenta durch folgendes Verfahren isolierbar: Beispiel 1 Plazentagewebe wurde nach der Geburt sofort tiefgefroren und bis zur Verwendung bei -200C gelagert.The collagen that can be used according to the invention is, for example, from human Placenta can be isolated by the following method: Example 1 Placental tissue was after Frozen immediately at birth and stored at -200C until use.
Nach dem Auftauen wurde von der Plazenta die Nabelschnur und entlang ihres Umfanges die fetalen Membranen abgeschnitten.After thawing, the placenta was down the umbilical cord and along their circumference cut off the fetal membranes.
Dem Zerhacken des Organes folgte die Auswaschung des Blutes mit 0,4 M Natriumacetatlösung Zuletzt wurde mit 0,5 ?i Ameisensäure gewaschen, un einen geeigneten pH-Wert für die Pepsinbehandlung einzustallen.The chopping of the organ was followed by the washing out of the blood with 0.4 M sodium acetate solution Finally, it was washed with 0.5 μl of formic acid, and one to establish a suitable pH for pepsin treatment.
10 kg feuchtes Gewebe wurden in 30 Liter 0,5 iW Ameinsensäure aufgeschwemmt und 1g Pepsin (0,1%) (aus der Magenschleimhaut des Schweines, 2500 Anson U/mg, Boehringer, mannhein) in Lösung zugefügt. liach einer Einwirkungsdauer von 16 - 20 Stunden be 20 0C wurde zentrifugiert und der feste Rückstand verworfen. Die nun folgenden Arbeiten wurden bei 50C im Kühlraum ausgeführt, um eine Benaturierung des Kollagens zu vermeiden. Das Zentrifugat wurde auf 6% natriumchloridkonzentration gebracht. Nach Zentrifugation wurde der Rückstand in 10 Liter o,o3 i Trishydroxymethylaminomethan/HCl-Puffer mit pH 7,6 und mit 0, 2 M NaCl-Gehalt gelöst. Der pH-Wert veränderte sich und wurde mit NaOH-Lösung nachgestellt.10 kg of moist tissue were suspended in 30 liters of 0.5 iW aminic acid and 1g pepsin (0.1%) (from the gastric mucosa of the pig, 2500 Anson U / mg, Boehringer, mannhein) added in solution. after an exposure time of 16-20 hours It was centrifuged at 20 ° C. and the solid residue was discarded. The following work were carried out at 50C in the cold room to avoid denaturing the collagen. The centrifugate was brought to 6% sodium chloride concentration. After centrifugation the residue was in 10 liters o, o3 i trishydroxymethylaminomethane / HCl buffer with pH 7.6 and dissolved with 0.2 M NaCl content. The pH changed and became adjusted with NaOH solution.
Die Probe wurde dann in Dialyseschläuchen gegen denselben Puffer (mehrmaliger Tirechsel) dialysiert, wobei einerseits das Pepsin inaktiviert und andererseits das überschüccige Natriumchlorid wegdilysiert wurden. Ein Niederschlag der sich während der Dialyse bildete, mußte abzentrifugiert werden. Es folgte die fraktionierte Salzfällung mit 1,8 H NaCl, Um Typ I Kollagen vollstandig zu entfernen, wurde dieser Schritt wiederholt. Die erforderlichen Zentrifugationen wurden bei 50,000g eine Stunde lang ausgeführt.The sample was then placed in dialysis tubes against the same buffer (several times Tirwechsel) dialyzed, on the one hand inactivating the pepsin and on the other hand the excess sodium chloride was diluted away. A precipitate of itself Formed during dialysis had to be centrifuged off. The fractional one followed Salt precipitation with 1.8 H NaCl. In order to completely remove type I collagen, this was done Step repeated. The required centrifugations were at 50,000g one Run for hour.
Der Rückstand, noch verunreinigt mit wenig Typ III Kollagens Lösung wurde/so wurde in 0,5 M Tris/FtCl, pH 8,0 gelöst und der viel 2-Mercaptoäthanol zugefügt, daß sie 0,02 molar war und inkubierte 20 Stunden bei 20°C Anschließend wurden die Sulfhydrylgruppen durch Zugabe von 0,018 M Jodacetat carboxymethyliert, Dauer 1 Stunde bei 200 G. Die Probe wurde in Dialyseschläuche gefüllt und gegen 0,5 M Ameisensäure dialysiert. Die Dialyseflüs sigke it wurde mehrmals gewechselt, um die überschüssigen Reagentien zu entfernen.The residue, still contaminated with a little type III collagen solution was / was dissolved in 0.5 M Tris / FtCl, pH 8.0 and the amount of 2-mercaptoethanol added that it was 0.02 molar and incubated for 20 hours at 20 ° C then the sulfhydryl groups were carboxymethylated by adding 0.018 M iodoacetate, Duration 1 hour at 200 G. The sample was filled into dialysis tubes and against Dialyzed 0.5 M formic acid. The dialysis fluid was changed several times, to remove the excess reagents.
Es folgte ein weiterer Pepsinabbau durch Zugabe von? mg Pepsin pro 1 g Naßgewicht des mit 1,8 M NaCl gefällten Niederschlages. Nach 16 - 20 Stunden Dauer der enzymatischen Behandlung wurde mit 6% NaCl das gesamte Kollagen ausgefällt.Another breakdown of pepsin followed by adding? mg pepsin per 1 g wet weight of the precipitate precipitated with 1.8 M NaCl. After 16-20 hours During the enzymatic treatment, all of the collagen was precipitated with 6% NaCl.
In einem anschließenden Schritt kann das so erhaltene Kollagen noch weiter gereinigt werden. Der erhaltene Rückstand wurde nochmals gelöst in 0,03 M Tris/HCl, pH 7,4, umdialysiefflt und bei 450C 1 Stunde denaturiert. Anschließend wurde die Lösung auf 3 N NaCl gebracht und über Nacht im Kühlrawn gerührt. Dabei fielen hochmolekulare Bestandteile aus der Lösung aus und konnten durch Zentrifugation entfernt werden.In a subsequent step, the collagen obtained in this way can still be used further cleaned. The residue obtained was redissolved in 0.03M Tris / HCl, pH 7.4, under dialysis and denatured at 450C for 1 hour. Afterward the solution was brought to 3N NaCl and stirred overnight in a refrigerator. Included high molecular weight components precipitated out of the solution and could by centrifugation removed.
Der verbliebene Uberstand Rann gegen 0,1 ìl-Essigsäure oder gegen 0,2 t Ammoniumhydrogencarbonatlösung dialysiert unter schließlich gefriergetrocknet werden. Auf diese Weise erhielt man reinster Basalmembrankollagen, welches zwecks Isolierung einzelner Teilkomponenten noch durch chromatographische Verfahren, wie Ionenaustauschchromatographie, Moleku1arsiebchromatogrphie, Elektrophorese etc., weiter aufgetrennt werden kann.The remaining supernatant ran against 0.1 ìl acetic acid or against 0.2 t ammonium hydrogen carbonate solution dialyzed and finally freeze-dried will. In this way, the purest basement membrane collagen was obtained Isolation of individual subcomponents by chromatographic methods, such as Ion exchange chromatography, molecular sieve chromatography, electrophoresis etc., can be further separated.
Je nach Intensivität der Pepsinbehandlungen werden verschiedengroße Peptidfragmente erhalten. Sowohl das native wie auch das denaturierte Kollagenmaterial kann durch übliche in der Proteinchemie bekannte Verfahren wie z. B. spez. proteolytische Enzyme, verdünnte Säuren, verdünnte Laugen, Bromcyan usw., weiter gespalten werden.Depending on the intensity of the pepsin treatments, they vary in size Obtain peptide fragments. Both the native and the denatured collagen material can by conventional methods known in protein chemistry such. B. spec. proteolytic Enzymes, dilute acids, dilute alkalis, cyanogen bromide, etc., can be further split.
Erfindungsgemäß kann selbstverständlich das Baalmembrankollagen in nativer als auch in denaturierter Form und gleichwohl in hochmolekularer Struktur als auch in teilweise gespaltener Form eingesetzt werden (Peptidgemisch, angereicherte Reinfraktionen) Das pharmakologisch wirksame Basalmembrankollagen kann in wäßrige und alkoholische Lösungen, Emulsionen, Salben und Puder und dergleichen eingearbeitet werden. Es kann auch in transparente Wundverschlußmittel aus vernetztem Polyäthylenoxid, wie in der DE-OS 1642155 beschrieben, einpolymerisiert werden.According to the invention, of course, the baalm membrane collagen in native as well as denatured form and nevertheless with a high molecular structure as well as in partially split form (peptide mixture, enriched Pure fractions) The pharmacologically active basement membrane collagen can be converted into aqueous and alcoholic solutions, emulsions, ointments and powders and the like are incorporated will. It can also be used in transparent wound closures made of cross-linked polyethylene oxide, how described in DE-OS 1642155, are polymerized.
Eine besonders praktische Anwendungsform stellen mit basalmembrankollagenhaltigen Präparaten getränkte bzw. imprägnierte Wundverbände und Pflaster dar. Durch bestimmte Trocknungsverfahren, z.B. Gefriertrocknung nach dem "spin-freezing"-Verfahren kann reines Basalmembrankollagen bzw. ein übliche Träger-und Hilfsstoffe enthaltendes Präparat in watteähnlicher Struktur erhalten werden. Aus diesen filzartigen Vliesen können dann Kissen verschiedenster Größe hergestellt werden, welche direkt zurWundabdeckung geeignet sind. Insbesondere SchUrfwunden, z.B. am Handrücken, welche oft sehr schlecht heilen, können vorteilhaft behandelt werden. Die Wunden hören auf zu schmerzen und trocknen schnell ab. Auch zur Blutstillung sind die Präparate hervoragend geeignet.A particularly practical form of application is with basement membrane collagen Preparations soaked or impregnated wound dressings and plasters. By certain Drying process, e.g. freeze-drying using the "spin-freezing" process pure basement membrane collagen or a conventional carrier and auxiliary material Preparation can be obtained in a cotton-wool-like structure. From these felt-like fleeces pillows of various sizes can then be produced, which are used directly to cover wounds are suitable. In particular, abrasions, e.g. on the back of the hand, which are often very bad heal can be treated beneficially. The wounds stop hurting and dry quickly. The preparations are also excellently suited for hemostasis.
Es ist selbstverständlich, daß nur sterile Präparate zum Einsatz kommen. Die Sterilisation kann nach herkömmlicher Art durch Zusatz von bactericiden, fungiciden und ähnlichen Mitteln gewährleistet werden. Besonders bevorzugt wird jedoch die Strahlungssterl isation anzuwenden sein.It goes without saying that only sterile preparations are used. The sterilization can be carried out in the conventional way by adding bactericidal, fungicidal and similar means are guaranteed. However, that is particularly preferred Radiation analysis must be applied.
Werden die erfindungsgemäßen Mittel für die Mundpflege, z.B. zur Behandlung von entzündetem Zahnfleisch oder bei Zahnfleischbluten verwendet, so werden die erfindungsgemäßen Mittel in Form von Mundwässern oder medizinischen Zahnpasten eingesetzt.If the compositions according to the invention are used for oral care, e.g. for treatment Used on inflamed gums or bleeding gums, the Agents according to the invention are used in the form of mouthwashes or medical toothpastes.
Auch bei Entzündungen der Bindehaut des Auges kann lurch Anwendung von verdünnten Lösungen, Z.B. in physiologischer Kochsalzlösung, von Basalmembrankollagen gute Erfolge erzielt werden.It can also be used for inflammation of the conjunctiva of the eye of dilute solutions, e.g. in physiological saline solution, of basement membrane collagen good results can be achieved.
Die nachfolgenden Beispiele sollen die erfindungsgemäße Verwendung des nach Beispiel 1 erhaltenen Basalmembrankollagens zeigen ohne die Erfindung in irgendeiner Weise einzuschränken: Beispiel 2 Creme mit wundheilender Wirkung, die insbesondere zur Behandlung von Hautverbrennungen geeignet ist. Es werden folgende Komponenten in ansich bekannter Weise zu einer Creme verarbeitet: Basalmembrankollagen (gemäß Beispiel 1) 1 g Paraffinöl 30 g Stearinsäure 8 g Triäthanolamin 1 g Duftstoff-(Rosenöl) 0,05g Polyvinypyrrolidon (PVP) 0,5 g Wasser, dest. ad 100 g Die Creme wurde bei externer Anwendung zur Behandlung von Sonnenbrand als angenehm kühlend empfunden und verhinderte weitgehend Bläschenbildung der Haut. Bei lokaler Anwendung bei Hautverbrennungen oder Abschürfungen zeigte sich eine sehr schöne Vernarbung und rasche Heilung.The following examples are intended to demonstrate the use according to the invention of the basement membrane collagen obtained according to Example 1 show without to limit the invention in any way: Example 2 Cream with wound healing Effect that is particularly suitable for treating skin burns. It the following components are processed into a cream in a manner known per se: Basement membrane collagen (according to Example 1) 1 g paraffin oil 30 g stearic acid 8 g triethanolamine 1 g perfume (rose oil) 0.05 g polyvinypyrrolidone (PVP) 0.5 g water, dist. ad 100 g The cream was found to be pleasant when applied externally for the treatment of sunburn felt cooling and largely prevented the formation of blisters on the skin. At local Use for skin burns or abrasions turned out to be very nice Scarring and rapid healing.
Beispiel 3 Zahnpaste, die bei regelmäßiger Anwendung Zahnfleischbluten verhindert: Basalmembrankollagen 0,1 g Vitamin C O,O5g Natriumfluorid 0,22g Calciumchlorid.gH20 1,8 g Carboxymethylcellulose 1,7 g Methyl-p-hydroxybenzoat 0,1 g Polymethylmethacrylatpulver 30 g Glycerin 10 g Wasser ad 100 g Beispiel 4 Mundwasser, geeignet zur Mundspülung bei wunden Stellen im Mund und Rachenraum sowie bei Neigung zu Zahnfleischbluten: Basalmembrankollagen 0,3 g Vitamin C 0,05g Aromastoffe 0,01g Kaliumdihydrogenphosphat 1 g Natriumlaurylsulfat 1 g Glycerin 3 g Äthanol 30 g Wasser ad 100 g Beispiel 5 Lotion, die nach dem Rasieren oder zur Behandlung von Hautabschürfungen verwendet wird: Quarternäres Polyvinylpyrrolidon Copolymerisat (Gafguat 755) 0,1 g Polystyrolsulfonat-Na-Salz 0,1 g (Flexan 500) Äthanol \ 2,5 g Basalmembrankollagen 0,1 g Wasser, dest. ad 100 g Beispiel 6 Lotion zum Tränken von Wundverbänden: Gafquat 755 0,05g Basalmembrankollagen 0,05g Carboxyvinylpolymeres (Carbopol 940) 0,04g Äthanol 2 g Polyäthylenglycol 1 g Allantoin 0,1 g Wasser ad 100 g Beispiel 7 Desinfektionslösung mit wundheilender Wirkung: Wundbenzin 100 g Basalmembrankollagen 5 g Beispiel 8 Wundpuder: Talkpulver 0,5 g Tonpulver 0,3 g Basalmembrankollagen (gefriergetrocknet) 0,2 g Beispiel 9 Reines nach Beispiel 1 hergestelltes Basalmembrankollagen wird in 0,1 M Essigsäure unter leichter Erwärmung gelöst.Example 3 Toothpaste that causes bleeding gums with regular use prevents: basement membrane collagen 0.1 g vitamin C O, O5 g sodium fluoride 0.22 g calcium chloride.gH20 1.8 g carboxymethyl cellulose 1.7 g methyl p-hydroxybenzoate 0.1 g polymethyl methacrylate powder 30 g glycerine 10 g water to 100 g Example 4 mouthwash, suitable for rinsing the mouth for sores in the mouth and throat as well as with a tendency to bleeding gums: Basement membrane collagen 0.3 g vitamin C 0.05 g flavoring substances 0.01 g potassium dihydrogen phosphate 1 g sodium lauryl sulfate 1 g glycerine 3 g ethanol 30 g water ad 100 g Example 5 Lotion used after shaving or to treat skin abrasions becomes: Quaternary polyvinylpyrrolidone copolymer (Gafguat 755) 0.1 g of polystyrene sulfonate sodium salt 0.1 g (Flexan 500) ethanol \ 2.5 g basement membrane collagen 0.1 g water, dist. ad 100 g Example 6 Lotion for soaking wound dressings: Gafquat 755 0.05 g basement membrane collagen 0.05g Carboxyvinyl polymer (Carbopol 940) 0.04 g ethanol 2 g polyethylene glycol 1 g of allantoin 0.1 g of water to 100 g of Example 7 Disinfectant solution with wound healing Effect: wound gasoline 100 g basement membrane collagen 5 g Example 8 wound powder: talc powder 0.5 g clay powder 0.3 g basement membrane collagen (freeze-dried) 0.2 g Example 9 Pure basement membrane collagen produced according to Example 1 is dissolved in 0.1 M acetic acid dissolved with slight warming.
Die Lösung wird nach dem " spin-freezing"-Ver£ahren eingefroren. Dabei wird unter Drehung aer Gefrietrocknungflasche in einem auf -20°C gekühlten Alkoholbad die Flüssigkeit als dünne Schicht an der Wand eingefroren. Nach Gefriertrocknung liegt ein dünner weißer, filzähnlicher Rückstand vor, welcher in verschieden große Kissen zerschnitten wurde.The solution is frozen according to the "spin-freezing" method. Included is rotated aer the freeze drying bottle in an alcohol bath cooled to -20 ° C the liquid Frozen as a thin layer on the wall. To Freeze-drying results in a thin, white, felt-like residue, which in different sized pillows were cut.
Nach Strahlungssterilisation (W-Licht) sind die Kissen zur Wundabdeckung einsetzbar.After radiation sterilization (UV light), the cushions are used to cover wounds applicable.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19813147727 DE3147727C2 (en) | 1980-12-06 | 1981-12-02 | Wound healing agents containing collagen from basement membranes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3050320 | 1980-12-06 | ||
DE19813147727 DE3147727C2 (en) | 1980-12-06 | 1981-12-02 | Wound healing agents containing collagen from basement membranes |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3147727A1 true DE3147727A1 (en) | 1983-02-17 |
DE3147727C2 DE3147727C2 (en) | 1986-04-03 |
Family
ID=25790141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19813147727 Expired DE3147727C2 (en) | 1980-12-06 | 1981-12-02 | Wound healing agents containing collagen from basement membranes |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE3147727C2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0206801A2 (en) * | 1985-06-21 | 1986-12-30 | Nitta Gelatin Inc. | Tissue-affinitive collagen for osteogenesis and method of producing the same |
EP0709101A2 (en) * | 1994-09-30 | 1996-05-01 | Sween Corporation | Heat stable wound care gel |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2712228A1 (en) * | 1977-03-19 | 1978-09-28 | Georg Dr Leiderer | Protein hydrolysate from collagen by strong acid hydrolysis - useful as additive for tooth-pastes, textile and hair washing compsns. |
-
1981
- 1981-12-02 DE DE19813147727 patent/DE3147727C2/en not_active Expired
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2712228A1 (en) * | 1977-03-19 | 1978-09-28 | Georg Dr Leiderer | Protein hydrolysate from collagen by strong acid hydrolysis - useful as additive for tooth-pastes, textile and hair washing compsns. |
Non-Patent Citations (3)
Title |
---|
Chemical Abstracts 80, 112686m, 1974 * |
Chemical Abstracts 91, 103943t, 1979 * |
CPJ-Basic Abstracts-Journal 1977, Nr.14951X/09 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0206801A2 (en) * | 1985-06-21 | 1986-12-30 | Nitta Gelatin Inc. | Tissue-affinitive collagen for osteogenesis and method of producing the same |
JPS6289629A (en) * | 1985-06-21 | 1987-04-24 | Nitta Zerachin Kk | Histotropic collagen and production thereof |
EP0206801A3 (en) * | 1985-06-21 | 1988-09-21 | Nitta Gelatin Inc. | Tissue-affinitive collagen for osteogenesis and method of producing the same |
US4975527A (en) * | 1985-06-21 | 1990-12-04 | Nitta Gelatin, Inc. | Tissue-affinitive collagen for osteogenesis and method of producing the same |
EP0709101A2 (en) * | 1994-09-30 | 1996-05-01 | Sween Corporation | Heat stable wound care gel |
EP0709101A3 (en) * | 1994-09-30 | 1996-07-24 | Sween Corp | Heat stable wound care gel |
Also Published As
Publication number | Publication date |
---|---|
DE3147727C2 (en) | 1986-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3689909T2 (en) | Use of a substance containing GHL-Cu for the manufacture of a medicament for wounds. | |
DE69839155T2 (en) | KERATIN-BASED HYDROGEL FOR BIOMEDICAL APPLICATIONS AND ITS MANUFACTURING METHOD | |
DE69127020T2 (en) | Milk protein hydrolyzates and compositions for use as hair and skin treatments | |
DE60015807T2 (en) | SOLUBLE KERATINEPEPTIDE | |
DE3032462C2 (en) | ||
US20030203008A1 (en) | Preparation of collagen | |
DE3788231T2 (en) | COSMETIC AGENT AND COMPOSITION FOR TREATING THE SKIN. | |
DE3032481A1 (en) | PREPARATION FOR THERAPEUTIC AND / OR COSMETIC APPLICATION TO LIVING BEINGS | |
JP7193662B2 (en) | Skin regenerating and healing mixture of peptide components and its use | |
EP1711190A1 (en) | Agent for treating inflammatory diseases | |
DE68913739T2 (en) | COSMETIC AND SKIN TREATMENT COMPOSITIONS. | |
DE69328228T2 (en) | Wound medication | |
EP1395231B1 (en) | Preparation for the removal of abnormal keratin material | |
DE1804801C3 (en) | Acne treatment agents | |
WO2010140724A1 (en) | Perm composition | |
DE60007973T2 (en) | MATRIX PROTEIN COMPOSITIONS FOR Grafting In Non-Mineralized Tissues | |
Chvapli et al. | Role of proteins in cosmetics | |
JPS5976007A (en) | Cosmetic | |
DE3937076A1 (en) | COLLAGEN, PROCESS FOR THEIR MANUFACTURE AND COSMETIC AGENTS | |
DE2804024A1 (en) | SKIN PROTEIN-BASED COSMETIC INGREDIENT | |
DE3147727C2 (en) | Wound healing agents containing collagen from basement membranes | |
DE69903166T2 (en) | METHOD FOR OBTAINING FIBRILLIN FROM CNIDARIA AND CORRESPONDING COSMETIC COMPOSITIONS | |
RU2295951C1 (en) | Composition for face and eyelids skin care | |
DE1667890C3 (en) | Dermatological and cosmetic topical preparations for the treatment of skin collagenoses | |
DE3046133C1 (en) | Cosmetic preparations containing collagen from basement membranes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
D2 | Grant after examination | ||
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |